Harris, NL, Jaffe, ES, Stein, H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361–1392.CrossRefGoogle ScholarPubMed

Swerdlow, SH, Williams, ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33: 7–20.CrossRefGoogle ScholarPubMed

van Leeuwen, MT, Turner, JJ, Joske, DJ, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer. 2014;135(9): 2146–2156.CrossRefGoogle ScholarPubMed

Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89: 3909-3918.CrossRefGoogle Scholar

Ohshima, K, Suzumiya, J, Sato, K, Kanda, M, Haraoka, S, Kikuchi, M. B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Lett. 1999;135: 73–81.CrossRefGoogle Scholar

Zhou, Y, Wang, H, Fang, W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113: 791–798.CrossRefGoogle ScholarPubMed

Argatoff, LH, Connors, JM, Klasa, RJ, Horsman, DE, Gascoyne, RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89: 2067–2078.CrossRefGoogle ScholarPubMed

Bosch, F, Lopez-Guillermo, A, Campo, E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82: 567–575.3.0.CO;2-Z>CrossRefGoogle Scholar

Romaguera, JE, Medeiros, LJ, Hagemeister, FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97: 586–591.CrossRefGoogle ScholarPubMed

Dreyling, M, Hiddemann, W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542–551.CrossRefGoogle Scholar

Leitch, HA, Gascoyne, RD, Chhanabhai, M, Voss, NJ, Klasa, R, Connors, JM. Limited-stage mantle-cell lymphoma. Ann Oncol. 2003;14: 1555–1561.CrossRefGoogle ScholarPubMed

Hoster, E, Dreyling, M, Klapper, W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111: 558–565.CrossRefGoogle ScholarPubMed

Hoster, E, Klapper, W, Hermine, O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32: 1338–1346.CrossRefGoogle ScholarPubMed

Royo, C, Salaverria, I, Hartmann, EM, Rosenwald, A, Campo, E, Bea, S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;21: 322–334.CrossRefGoogle ScholarPubMed

Rosenwald, A, Wright, G, Wiestner, A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3: 185–197.CrossRefGoogle ScholarPubMed

Jares, P, Campo, E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142: 149–165.CrossRefGoogle ScholarPubMed

Klapper, W, Hoster, E, Determann, O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2: 103–111.CrossRefGoogle ScholarPubMed

Cohen, JB, Ruppert, AS, Heerema, NA, et al. Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts. 2012.CrossRefGoogle Scholar

Espinet, B, Salaverria, I, Bea, S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49: 439–451.CrossRefGoogle Scholar

Dreyling, M, Thieblemont, C, Gallamini, A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24: 857–877.CrossRefGoogle ScholarPubMed

Herrmann, A, Hoster, E, Zwingers, T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27: 511–518.CrossRefGoogle ScholarPubMed

Lenz, G, Dreyling, M, Hoster, E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23: 1984–1992.CrossRefGoogle ScholarPubMed

Tam, CS, Bassett, R, Ledesma, C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113: 4144–4152.CrossRefGoogle Scholar

Schulz, H, Bohlius, JF, Trelle, S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99: 706–714.CrossRefGoogle ScholarPubMed

Lefrere, F, Delmer, A, Suzan, F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16: 587–593.CrossRefGoogle ScholarPubMed

van ’t Veer, MB, de Jong, D, MacKenzie, M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009;144: 524–530.CrossRefGoogle ScholarPubMed

Eskelund, CW, Kolstad, A, Jerkeman, M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; July 5. doi: 10.1111/bjh.14241.CrossRefGoogle Scholar

Hermine, O, Hoster, E, Walewski, J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016; Aug 6;388(10044):565–75. doi: 10.1016/S0140-6736(16)00739-X.CrossRefGoogle ScholarPubMed

Chihara, D, Cheah, CY, Westin, JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan;172(1):80–8. doi: 10.1111/bjh.13796.CrossRefGoogle ScholarPubMed

Bernstein, SH, Epner, E, Unger, JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24: 1587–1593.CrossRefGoogle ScholarPubMed

Merli, F, Luminari, S, Ilariucci, F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156: 346–353.CrossRefGoogle ScholarPubMed

Chang, JE, Li, H, Smith, MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123: 1665–1673.CrossRefGoogle Scholar

Kenkre, VP, Long, WL, Eickhoff, JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011;52: 1675–1680.CrossRefGoogle ScholarPubMed

Jantunen, E, Canals, C, Attal, M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23: 166–171.CrossRefGoogle Scholar

Rummel, MJ, Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381: 1203–1210.CrossRefGoogle Scholar

Flinn, IW, van der Jagt, R, Kahl, BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123: 2944–2952.CrossRefGoogle ScholarPubMed

Burke, JM, Van der Jagt, RH, Kahl, BS, et al. Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin’s lymphoma or mantle cell lymphoma. ASH Annual Meeting Abstracts. 2012;120: 155.Google Scholar

Cavalli, F, Rooney, B, Pei, L, Van De Velde, H, Robak, T. Investigators aobotL. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). ASCO Meeting Abstracts. 2014;8500.CrossRefGoogle Scholar

Visco, C, Finotto, S, Zambello, R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31: 1442–1449.CrossRefGoogle ScholarPubMed

Kluin-Nelemans, HC, Hoster, E, Hermine, O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367: 520–531.CrossRefGoogle ScholarPubMed

Martin, P, Smith, M, Till, B. Management of mantle cell lymphoma in the elderly. Best Pract Res Clin Haematol. 2012;25: 221–231.CrossRefGoogle ScholarPubMed

Weidmann, E, Neumann, A, Fauth, F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22: 1839–1844.CrossRefGoogle ScholarPubMed

Ghielmini, M, Zucca, E. How I treat mantle cell lymphoma. Blood. 2009;114: 1469–1476.CrossRefGoogle Scholar

Ghielmini, M, Schmitz, SF, Cogliatti, S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23: 705–711.CrossRefGoogle ScholarPubMed

Dreyling, M, Lenz, G, Hoster, E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105: 2677–2684.CrossRefGoogle ScholarPubMed

Hoster, E, Metzner, B, Forstpointner, R, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114: 880.CrossRefGoogle Scholar

Fenske, TS, Zhang, MJ, Carreras, J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32: 273–281.CrossRefGoogle ScholarPubMed

LaCasce, AS, Vandergrift, JL, Rodriguez, MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119: 2093–2099.CrossRefGoogle ScholarPubMed

Geisler, CH, Kolstad, A, Laurell, A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112: 2687–2693.CrossRefGoogle ScholarPubMed

Ladetto, M, Magni, M, Pagliano, G, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant. 2006;12: 1270–1276.CrossRefGoogle ScholarPubMed

Andersen, NS, Pedersen, LB, Laurell, A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27: 4365–4370.CrossRefGoogle ScholarPubMed

Dietrich, S, Weidle, J, Rieger, M, et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia. 2014;28: 708–709.CrossRefGoogle ScholarPubMed

Le Gouill, S, Thieblemont, G, Oberic, L, et al. Maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of randomized phase 3 LyMa trial of the Lysa/Goelams group. ASH Annual Meeting Abstracts, 2016 [Abstract 145].CrossRefGoogle Scholar

Rubio Marie, T, Boumendil, A, Luan, JJ, et al. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the Lymphoma Working Party of the EBMT. ASH Annual Meeting Abstracts. 2010;116:688.Google Scholar

Hoster, E, Geisler, Christian H, Doorduijn, Jeanette K, et al. Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma: a comparison of nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood. 2013;122: 3367.CrossRefGoogle Scholar

Kolstad, A, Laurell, A, Jerkeman, M, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123: 2953–2959.CrossRefGoogle ScholarPubMed

Khouri, IF, Lee, MS, Romaguera, J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999;10: 1293–1299.CrossRefGoogle ScholarPubMed

Khouri, IF, Lee, MS, Saliba, RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21: 4407–4412.CrossRefGoogle ScholarPubMed

Maris, MB, Sandmaier, BM, Storer, BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104: 3535–3542.CrossRefGoogle ScholarPubMed

Dietrich, S, Boumendil, A, Finel, H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25: 1053–1058.CrossRefGoogle Scholar

Le Gouill, S, Kroger, N, Dhedin, N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol. 2012;23: 2695–2703.CrossRefGoogle ScholarPubMed

Hari, PN , Maloney, DG , Carreras, J, et al. Allogeneic transplantation (AlloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation (AutoHCT). on behalf of the writing committee, Center for International Blood & Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI 11th International Conference on Malignant Lymphoma. Lugano, Switzerland. Ann Oncol 2011;Suppl 4:Abstract 038.Google Scholar

Hamadani, M, Saber, W, Ahn, KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19: 625–631.CrossRefGoogle ScholarPubMed

Perez-Galan, P, Dreyling, M, Wiestner, A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117: 26–38.CrossRefGoogle ScholarPubMed

Wang, ML, Rule, S, Martin, P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369: 507–516.CrossRefGoogle ScholarPubMed

Hess, G, Herbrecht, R, Romaguera, J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27: 3822–3829.CrossRefGoogle ScholarPubMed

Renner, C, Zinzani, PL, Gressin, R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97: 1085–1091.CrossRefGoogle ScholarPubMed

Goy, A, Bernstein, SH, Kahl, BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20: 520–525.CrossRefGoogle ScholarPubMed

Goy, A, Sinha, R, Williams, ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31: 3688–3695.CrossRefGoogle ScholarPubMed

Wang, M, Fayad, L, Wagner-Bartak, N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13: 716–723.CrossRefGoogle ScholarPubMed

Wang, M, Oki, Y, Pro, B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27: 5213–5218.CrossRefGoogle ScholarPubMed

Kahl, BS, Spurgeon, SE, Furman, RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123: 3398–3405.CrossRefGoogle ScholarPubMed

Evens, AM, Vose, JM, Harb, W, et al. A Phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts. 2012;120: 55.Google Scholar

Davids, MS, Seymour, JF, Gerecitano, JF, et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood. 2013;122(21)1789.CrossRefGoogle Scholar

Robinson, S, Dreger, P, Caballero, D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29(2):464–473.CrossRefGoogle ScholarPubMed

Kruger, WH, Hirt, C, Basara, N, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014;93(9): 1587–1597.CrossRefGoogle Scholar

Dreyling, M. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book. 2014: 191–198.CrossRefGoogle Scholar

Tiemann, M, Schrader, C, Klapper, W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131: 29–38.CrossRefGoogle ScholarPubMed

Jares, P, Colomer, D, Campo, E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7: 750–762.CrossRefGoogle ScholarPubMed

Fernàndez, V, Salamero, O, Espinet, B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70: 1408–1418.CrossRefGoogle ScholarPubMed

Ondrejka, SL, Lai, R, Smith, SD, Hsi, ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96: 1121–1127.CrossRefGoogle ScholarPubMed

Nygren, L, Baumgartner Wennerholm, S, Klimkowska, M, Christensson, B, Kimby, E, Sander, B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119: 4215–4223.CrossRefGoogle Scholar

Martin, P, Chadburn, A, Christos, P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27: 1209–1213.CrossRefGoogle ScholarPubMed

Swerdlow, SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: World Health Organization, 2008.Google Scholar

Cheah, CY, George, A, Gine, E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013;24: 2119–2123.CrossRefGoogle ScholarPubMed

Conconi, A, Franceschetti, S, Lobetti-Bodoni, C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma. 2013;54: 1908–1914.CrossRefGoogle ScholarPubMed

Ferrer, A, Bosch, F, Villamor, N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008;19: 135–141.CrossRefGoogle ScholarPubMed

Vose, JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012;87: 604–609.CrossRefGoogle ScholarPubMed

Schlette, E, Lai, R, Onciu, M, Doherty, D, Bueso-Ramos, C, Medeiros, LJ. Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol. 2001;14: 1133–1140.CrossRefGoogle ScholarPubMed

Bernard, M, Tsang, RW, Le, LW, et al. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma. 2013;54: 261–267.CrossRefGoogle ScholarPubMed

Damon, LE, Johnson, JL, Niedzwiecki, D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27: 6101–6108.CrossRefGoogle ScholarPubMed

Delarue, R, Haioun, C, Ribrag, V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121: 48–53.CrossRefGoogle ScholarPubMed

Gressin, R, Caulet-Maugendre, S, Deconinck, E, et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010;95: 1350–1357.CrossRefGoogle Scholar

Vandenberghe, E, Ruiz de Elvira, C, Loberiza, FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120: 793–800.CrossRefGoogle ScholarPubMed

Touzeau, C, Leux, C, Bouabdallah, R, et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol. 2014;93: 233–242.CrossRefGoogle ScholarPubMed

Herold, M, Haas, A, Srock, S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25: 1986–1992.CrossRefGoogle Scholar

Smith, MR, Li, H, Gordon, L, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30: 3119–3126.CrossRefGoogle Scholar

Houot, R, Le Gouill, S, Ojeda Uribe, M, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012;23: 1555–1561.CrossRefGoogle Scholar

Ruan, J, Gregory, SA, Christos, P, et al. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clin Lymphoma Myeloma Leuk. 2014;14: 107–113.CrossRefGoogle ScholarPubMed

Cook, G, Smith, GM, Kirkland, K, et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;16: 1419–1427.CrossRefGoogle ScholarPubMed

Hamadani, M, Saber, W, Ahn, KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2013;19: 625–631.CrossRefGoogle ScholarPubMed

Forstpointner, R, Unterhalt, M, Dreyling, M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108: 4003–4008.CrossRefGoogle Scholar

Robinson, KS, Williams, ME, van der Jagt, RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26: 4473–4479.CrossRefGoogle ScholarPubMed

Rummel, MJ, Al-Batran, SE, Kim, SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23: 3383–3389.CrossRefGoogle Scholar

Thomas, DW, Owen, RG, Johnson, SA, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma. 2005;46: 549–552.CrossRefGoogle ScholarPubMed

Kouroukis, CT, Fernandez, LA, Crump, M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52: 394–399.CrossRefGoogle Scholar

Hitz, F, Martinelli, G, Zucca, E, et al. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematol Oncol. 2009;27: 154–159.CrossRefGoogle ScholarPubMed

Garbo, LE, Flynn, PJ, MacRae, MA, Rauch, MA, Wang, Y, Kolibaba, KS. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest New Drugs. 2009;27: 476–481.CrossRefGoogle ScholarPubMed

Rodriguez, J, Gutierrez, A, Palacios, A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma. 2007;48: 2172–2178.CrossRefGoogle ScholarPubMed

Morschhauser, F, Depil, S, Jourdan, E, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol. 2007;18: 370–375.CrossRefGoogle ScholarPubMed

Lamm, W, Kaufmann, H, Raderer, M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011;96: 1008–1014.CrossRefGoogle ScholarPubMed

Friedberg, JW, Vose, JM, Kelly, JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117: 2807–2812.CrossRefGoogle ScholarPubMed

Baiocchi, RA, Alinari, L, Lustberg, ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117: 2442–2451.CrossRefGoogle ScholarPubMed

Zinzani, PL, Vose, JM, Czuczman, MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24: 2892–2897.CrossRefGoogle ScholarPubMed

Zaja, F, De Luca, S, Vitolo, U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97: 416–422.CrossRefGoogle ScholarPubMed

Ruan, J, Martin, P, Coleman, M, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116: 2655–2664.CrossRefGoogle ScholarPubMed

Witzig, TE, Geyer, SM, Ghobrial, I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23: 5347–5356.CrossRefGoogle ScholarPubMed

Ansell, SM, Tang, H, Kurtin, PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12: 361–368.CrossRefGoogle ScholarPubMed

Ansell, SM, Inwards, DJ, Rowland, KM Jr., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113: 508–514.CrossRefGoogle ScholarPubMed

Morschhauser, FA, Cartron, G, Thieblemont, C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31: 2912–2919.CrossRefGoogle ScholarPubMed

Chen, RW, Hongli, L, Bernstein, SH, Rimsza, LM, Foreman, SJ, Constine, L, et al. BR but not R-HCVAD is a feasible induction prior to ASCT in frontline MCL: Results of SWOG study 1106. Br J Haematol; in press.Google Scholar

Robak, T, Huang, H, Jin, J, Zhu, J, Liu, T, Samoilova, O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53.CrossRefGoogle ScholarPubMed

Ruan, J, Martin, P, Shah, B, Chuster, SJ, Smith, SM, Furman, RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–44.CrossRefGoogle ScholarPubMed